We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Canopy Growth Corporation (CGC) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
Canopy Growth Corporation (CGC - Free Report) ended the recent trading session at $1.03, demonstrating a -1.9% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.37%. At the same time, the Dow lost 0.74%, and the tech-heavy Nasdaq lost 0.03%.
The stock of company has fallen by 11.77% in the past month, lagging the Medical sector's loss of 0.88% and the S&P 500's gain of 2.68%.
The investment community will be closely monitoring the performance of Canopy Growth Corporation in its forthcoming earnings report. The company is scheduled to release its earnings on August 8, 2025. The company is forecasted to report an EPS of -$0.15, showcasing a 59.46% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $47.91 million, down 0.99% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.46 per share and revenue of $198.45 million, which would represent changes of +84.56% and +2.66%, respectively, from the prior year.
Any recent changes to analyst estimates for Canopy Growth Corporation should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 11.38% lower. At present, Canopy Growth Corporation boasts a Zacks Rank of #4 (Sell).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 183, putting it in the bottom 26% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Canopy Growth Corporation (CGC) Registers a Bigger Fall Than the Market: Important Facts to Note
Canopy Growth Corporation (CGC - Free Report) ended the recent trading session at $1.03, demonstrating a -1.9% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 0.37%. At the same time, the Dow lost 0.74%, and the tech-heavy Nasdaq lost 0.03%.
The stock of company has fallen by 11.77% in the past month, lagging the Medical sector's loss of 0.88% and the S&P 500's gain of 2.68%.
The investment community will be closely monitoring the performance of Canopy Growth Corporation in its forthcoming earnings report. The company is scheduled to release its earnings on August 8, 2025. The company is forecasted to report an EPS of -$0.15, showcasing a 59.46% upward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $47.91 million, down 0.99% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.46 per share and revenue of $198.45 million, which would represent changes of +84.56% and +2.66%, respectively, from the prior year.
Any recent changes to analyst estimates for Canopy Growth Corporation should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 11.38% lower. At present, Canopy Growth Corporation boasts a Zacks Rank of #4 (Sell).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 183, putting it in the bottom 26% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.